Market Cap 36.08M
Revenue (ttm) 2.27M
Net Income (ttm) -59.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,625.55%
Debt to Equity Ratio -1.23
Volume 695,800
Avg Vol 1,526,178
Day's Range N/A - N/A
Shares Out 21.87M
Stochastic %K 18%
Beta 0.18
Analysts Strong Sell
Price Target $14.80

Company Profile

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 475 238 6837
Address:
555 Long Wharf Drive, 12th Floor, New Haven, United States
elronjr
elronjr Mar. 21 at 8:00 PM
$OCGN $BTAI $HUMA $BMEA $NOTE I took a beating this week. Note is as per usual garbage and a lost cause at this point. Really hoping earnings reports this week for $BTAI $HUMA $BMEA pull through and actually save me. This is an absolute shitshow. Humacyte probably has the dumbest people running the company. I’m hoping they have something up their sleeve this ER to have that damn stock go above 1-1.5$
1 · Reply
AllAboutTheBread
AllAboutTheBread Mar. 20 at 5:53 PM
$BTAI lol not in our lifetime. but 8 is.
1 · Reply
WenABVEAudit
WenABVEAudit Mar. 20 at 3:39 PM
$BTAI is $17 a reasonable achievable pt?
6 · Reply
11thestate
11thestate Mar. 20 at 3:05 PM
When we see a stock like this, we know how many damaged investors are out there. Believe it or not, there's some good news. $BTAI investors — you might be surprised, but you actually have a chance to recover your losses. Don't miss it: https://11th.com/cases/bioxcel-investor-settlement
0 · Reply
AllAboutTheBread
AllAboutTheBread Mar. 20 at 2:56 PM
$BTAI balls deep at 1.55, didnt think it would get back down so quick but ill take this free gift
1 · Reply
PolyesterJacket
PolyesterJacket Mar. 20 at 2:16 PM
$BTAI only 285k shares available for borrowing. Let's buy them up and start a short squeeze.
0 · Reply
AllAboutTheBread
AllAboutTheBread Mar. 20 at 3:22 AM
$BTAI went heavy today at 1.56, cant say im mad about it
0 · Reply
FastRocketTraders
FastRocketTraders Mar. 19 at 7:20 PM
$BTAI swing it
0 · Reply
TraderNice
TraderNice Mar. 19 at 6:30 PM
$BTAI Soon FDA will give us a thumbs up, that they recieved the fda application and they are moving forward to make a decision on the approval or not. FDA will have to make a decision in 6 months, that will be this Summer in July…I believe the application was sent around February 15th
1 · Reply
StMichaelTwits
StMichaelTwits Mar. 19 at 6:21 PM
$BTAI 👇😘Shhhhhhhhh 🤫 "The company received positive written feedback from the FDA on its pre-sNDA package, confirming that the proposed clinical, nonclinical, and chemistry-manufacturing-and-controls information and formatting meet regulatory expectations. With FDA alignment secured, BioXcel believes the completed submission will support acceptance and review without needing an additional meeting."
0 · Reply
Latest News on BTAI
Why Are BioXcel Therapeutics Shares Down Friday?

Mar 6, 2026, 10:27 AM EST - 15 days ago

Why Are BioXcel Therapeutics Shares Down Friday?


BioXcel Therapeutics Stock Rallies Opioid Study Success

Mar 5, 2026, 8:53 AM EST - 16 days ago

BioXcel Therapeutics Stock Rallies Opioid Study Success


BioXcel Seeks FDA Label Expansion For Schizophrenia Treatment

Aug 27, 2025, 12:01 PM EDT - 7 months ago

BioXcel Seeks FDA Label Expansion For Schizophrenia Treatment


BioXcel's agitation drug meets main goal in at-home study

Aug 27, 2025, 7:29 AM EDT - 7 months ago

BioXcel's agitation drug meets main goal in at-home study


BioXcel Therapeutics Announces Reverse Stock Split

Feb 6, 2025, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Announces Reverse Stock Split


BioXcel Therapeutics Announces Proposed Public Offering

Nov 21, 2024, 4:47 PM EST - 1 year ago

BioXcel Therapeutics Announces Proposed Public Offering


BioXcel Therapeutics to Present at ThinkEquity Conference

Oct 29, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics to Present at ThinkEquity Conference


elronjr
elronjr Mar. 21 at 8:00 PM
$OCGN $BTAI $HUMA $BMEA $NOTE I took a beating this week. Note is as per usual garbage and a lost cause at this point. Really hoping earnings reports this week for $BTAI $HUMA $BMEA pull through and actually save me. This is an absolute shitshow. Humacyte probably has the dumbest people running the company. I’m hoping they have something up their sleeve this ER to have that damn stock go above 1-1.5$
1 · Reply
AllAboutTheBread
AllAboutTheBread Mar. 20 at 5:53 PM
$BTAI lol not in our lifetime. but 8 is.
1 · Reply
WenABVEAudit
WenABVEAudit Mar. 20 at 3:39 PM
$BTAI is $17 a reasonable achievable pt?
6 · Reply
11thestate
11thestate Mar. 20 at 3:05 PM
When we see a stock like this, we know how many damaged investors are out there. Believe it or not, there's some good news. $BTAI investors — you might be surprised, but you actually have a chance to recover your losses. Don't miss it: https://11th.com/cases/bioxcel-investor-settlement
0 · Reply
AllAboutTheBread
AllAboutTheBread Mar. 20 at 2:56 PM
$BTAI balls deep at 1.55, didnt think it would get back down so quick but ill take this free gift
1 · Reply
PolyesterJacket
PolyesterJacket Mar. 20 at 2:16 PM
$BTAI only 285k shares available for borrowing. Let's buy them up and start a short squeeze.
0 · Reply
AllAboutTheBread
AllAboutTheBread Mar. 20 at 3:22 AM
$BTAI went heavy today at 1.56, cant say im mad about it
0 · Reply
FastRocketTraders
FastRocketTraders Mar. 19 at 7:20 PM
$BTAI swing it
0 · Reply
TraderNice
TraderNice Mar. 19 at 6:30 PM
$BTAI Soon FDA will give us a thumbs up, that they recieved the fda application and they are moving forward to make a decision on the approval or not. FDA will have to make a decision in 6 months, that will be this Summer in July…I believe the application was sent around February 15th
1 · Reply
StMichaelTwits
StMichaelTwits Mar. 19 at 6:21 PM
$BTAI 👇😘Shhhhhhhhh 🤫 "The company received positive written feedback from the FDA on its pre-sNDA package, confirming that the proposed clinical, nonclinical, and chemistry-manufacturing-and-controls information and formatting meet regulatory expectations. With FDA alignment secured, BioXcel believes the completed submission will support acceptance and review without needing an additional meeting."
0 · Reply
StMichaelTwits
StMichaelTwits Mar. 19 at 6:16 PM
$BTAI buy when it looks ugly..why? 👇 Drug: BXCL501 (SERENITY) Announced Date: August 18, 2025 Target Action Date: Q1 2026 Estimated Target Date Range: January 1, 2026 - 👉March 31, 2026👈
0 · Reply
SrTxan
SrTxan Mar. 19 at 4:40 PM
$BTAI I don’t really understand this obsession with saying this will happen in the summer. Yesterday you said July, today you say summer. Do you know something the rest of us don’t? Why summer and not next week? It almost sounds like you’re trying to make people think this is months away, when that might not necessarily be the case. That said, if you actually have reliable information suggesting it will happen in the summer and you’re willing to share it, it would obviously be welcome.
1 · Reply
TraderNice
TraderNice Mar. 19 at 4:10 PM
$BTAI Well, this is good information about this stock. I think the Director will help with the commercialization this summer, with his contacts. The fda approved drug itself is very good and should be making more revenue, hopefully this will change with the new Director.
0 · Reply
SrTxan
SrTxan Mar. 19 at 2:51 PM
$BTAI About Pavao: One interesting detail is that he was appointed Interim Chief Commercial Officer, not permanent. In biotech this is usually done for a reason, and it typically points to three possible strategic scenarios. 1. Preparation for commercialization Companies often bring in experienced executives temporarily to prepare the launch of a drug, structure the commercial team, pricing strategy and market access before the product expands into a larger market. 2. Partnership negotiations Executives with strong big pharma backgrounds are frequently hired to lead or assist in partnership discussions with larger pharmaceutical companies. Their experience and network can be key during those negotiations. 3. Strategic transition phase Sometimes companies use interim executives during key regulatory or strategic milestones, when they expect the company structure to change afterwards, for example after an approval, partnership, or commercialization expansion.
1 · Reply
SrTxan
SrTxan Mar. 19 at 10:00 AM
$BTAI About the earnings I’ll just say one thing. In the last reported results, if I remember correctly, they said IGALMI generated about $98,000 in revenue. So maybe I’m just a simple guy, but I ask myself something… If the CEO alone makes around $1 million per year, and that doesn’t even include the rest of the executives who are also very well paid… how exactly does that work? Maybe there are some numbers we’re not seeing yet, right? Let’s see if Pavao manages to bring some order to the ship, and more importantly, what happens with the sNDA, which is the only thing that really matters here. Because right now we’re being flooded with noise to keep us distracted. Offerings, earnings, partnerships, price targets… All of it seems designed to make us lose sight of the only thing that actually matters. The sNDA. Everything else right now is just cheap noise to keep us distracted.
1 · Reply
TraderNice
TraderNice Mar. 19 at 5:21 AM
$BTAI I think you are confuse or on the wrong site. Most people who invested in this particular stock are hoping they have a partnership. Also….well just move on
0 · Reply
AllAboutTheBread
AllAboutTheBread Mar. 19 at 1:21 AM
$BTAI what are you talking about? thats complete misinformation, people have gotten sued for saying stuff like that before on forums.
0 · Reply
AllAboutTheBread
AllAboutTheBread Mar. 18 at 11:14 PM
$BTAI anyways, i still bought more today on the dip to 1.60. i’ve waited this long already.
0 · Reply
TraderNice
TraderNice Mar. 18 at 8:53 PM
$BTAI Maybe, but the partnership and no offering will be interesting during the earning call
0 · Reply
AllAboutTheBread
AllAboutTheBread Mar. 18 at 7:44 PM
$BTAI earnings will always be bad here. so not much of a catalyst.
0 · Reply
SrTxan
SrTxan Mar. 18 at 7:09 PM
$BTAI The Day 74 letter is not an approval timeline and it definitely does not mean the FDA will get back to you in July. What the Day 74 letter actually means is very simple. The FDA has completed the filing review and confirms that the application has been accepted for review. It is basically an administrative checkpoint confirming that the submission is complete enough for the FDA to start the review process. But it is not the decision and it does not delay the decision to July. For a supplemental NDA (sNDA) like the IGALMI at-home submission from BioXcel, the review timeline is much shorter than a full NDA. So the idea that the FDA is basically saying everything is fine, we’ll get back to you in July, is simply wrong. That interpretation confuses the filing acceptance step with the actual review timeline and creates a misleading impression about when a decision could happen.
1 · Reply
TraderNice
TraderNice Mar. 18 at 6:12 PM
$BTAI I thought the earning report is out Friday Morning? This is a big deal. Why? Is there more revenue this quarter from your fda product? Do you have a new partner? After the initial offering last week, do we have enough money for Commercialization in July?
0 · Reply